Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251208 | 0.85 | HTR2A (0.36) | HTR2AHTR2CHTR2BGSK3B | |
| SCHEMBL19250878 | 0.82 | HTR2A (0.42) | HTR2AHTR2CHTR2BMEN1ALDH1A1 | |
| SCHEMBL11886343 | 0.82 | HTR2A (0.42) | HTR2AHTR2CHTR2BMEN1ALDH1A1 | |
| SCHEMBL19250881 | 0.82 | HTR2A (0.42) | HTR2AHTR2CHTR2BMEN1ALDH1A1 | |
| SCHEMBL19251265 | 0.82 | HTR2A (0.42) | HTR2AHTR2CHTR2BMEN1ALDH1A1 | |
| SCHEMBL27094595 | 0.78 | P2RX7 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL27094569 | 0.78 | P2RX7 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL27094563 | 0.78 | P2RX7 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL19851847 | 0.75 | HTR2A (0.38) | HTR2AHTR2CHTR2BMEN1ALDH1A1 | |
| SCHEMBL6177530 | 0.75 | HTR2A (0.36) | HTR2AHTR2CHTR2BKMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | HTR2A 4068/4885HTR2C 4366/4885HTR2B 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.